Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Center, Open-label, Single Sequence Study to Evaluate the Potential Drug Interaction of CYP3A4 Inducer Rifampicin With SY-004 Capsules in Healthy Subjects

NCT04907019 is registered in ClinicalTrials.gov with Suzhou Yabao Pharmaceutical R&D Co., Ltd. as lead sponsor.

NCT NCT04907019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04907019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Center, Open-label, Single Sequence Study to Evaluate the Potential Drug Interaction of CYP3A4 Inducer Rifampicin With SY-004 Capsules in Healthy Subjects
Lead sponsor
Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
July 6, 2021
Completion date
August 17, 2021
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes